Association of hypertension with overall outcome in patients taking sorafenib in advanced hepatocellular carcinoma (HCC)

被引：3
|
作者：
Kim, R. D.
Byrne, M. T.
Hammel, J.
El-Gazzaz, G.
Aucejo, F.
机构：
[1] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[2] Cleveland Clin, Cleveland, OH 44106 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e14536
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14536
引用
收藏
页数：1
相关论文
共 50 条
  • [1] SORAFENIB TREATMENT FOR HEPATOCELLULAR CARCINOMA (HCC) IN PATIENTS WITH ADVANCED LIVER DISEASE
    Alves, Rogerio C.
    Alves, Daniele E.
    Guz, Betty
    Viana, Monica V.
    Harriz, Michelle C.
    Matos, Carla A.
    Terrabuio, Deborah
    Chagas, Aline
    Moutinho, Renata D.
    Taddeo, Eliane F.
    Duarte, Kelly C.
    Oliveira, George P.
    Ribeirol, Juliana M.
    Kondo, Mario
    Gampel, Otavio
    Poletti, Paula
    HEPATOLOGY, 2010, 52 (04) : 1193A - 1193A
  • [2] Outcomes and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma (HCC)
    Ziogas, Dimitrios
    Thillai, Kiruthikah
    Korantzis, Ippokratis
    Chowdhury, M. H. Ruhe
    Papadatos-Pastos, Dionysios
    Suddle, Abid
    O'Grady, John
    Heaton, Nigel
    Ross, Paul J.
    Sarker, Debashis
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [3] Outcomes and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma (HCC)
    Ziogas, Dimitris
    Thillai, Kiruthikah
    Papadatos-Pastos, Dionysios
    Chowdhury, Mahfuja Hussain Ruhe
    Korantzis, Ippokratis
    Manickavasagar, Thubeena
    Suddle, Abid
    O'Grady, John
    Heaton, Nigel
    Ross, Paul J.
    Sarker, Debashis
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Relationship between ethnicity and overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S).
    Meyers, Daniel E.
    Lee-Ying, Richard M.
    Alghamdi, Mohammed Abdullah
    Cheung, Winson Y.
    Samawi, Haider
    Tam, Vincent C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [5] A phase I study of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Yopp, Adam
    Arriega, Yuii
    Singal, Amit
    Mansour, John
    Bach, Glen
    Thorpe, Phillip
    CANCER RESEARCH, 2012, 72
  • [6] Sorafenib in advanced hepatocellular carcinoma (HCC) : Ascites as prognostic factor
    Koch, S.
    Niederle, I.
    Gamstaetter, T.
    Schuchmann, M.
    Galle, P.
    Woerns, M.
    Weinmann, A.
    INTERNIST, 2013, 54 (06): : 745 - 745
  • [7] Sorafenib in advanced hepatocellular carcinoma (HCC) : Ascites as prognostic factor
    Koch, S.
    Niederle, I.
    Gamstaetter, T.
    Schuchmann, M.
    Galle, P.
    Woerns, M.
    Weinmann, A.
    INTERNIST, 2013, 54 : 10 - 10
  • [8] Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma
    Peixoto, Renata D'Alpino
    Renouf, Daniel J.
    Gill, Sharlene
    Cheung, Winson Y.
    Lim, Howard J.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2014, 5 (04) : 259 - 264
  • [9] Relationship of ethnicity and overall survival (OS) in Asian patients (pts) on sorafenib for advanced hepatocellular carcinoma (HCC) in British Columbia, Canada
    Peixoto, Renata D'Alpino
    Renouf, Daniel John
    Gill, Sharlene
    Cheung, Winson Y.
    Kennecke, Hagen F.
    Lim, Howard John
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [10] Concomitant use of antiacids in patients with advanced hepatocellular carcinoma (HCC) receiving sorafenib therapy
    Razak, Razwan Abd
    Kunene, Victoria
    Ma, Yuk Ting
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345